Advice
in the absence of a submission from the holder of the marketing authorisation:
azacitidine (Vidaza®) is not recommended for use within NHS Scotland.
Indication under review: Treatment of adult patients aged 65 years or older who are not eligible for haematopoietic stem cell transplantation (HSCT) with acute myeloid leukaemia (AML) with >30% marrow blasts according to the World Health Organisation (WHO) classification.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this setting. As a result we cannot recommend its use within NHSScotland.
Download detailed advice110KB (PDF)
Medicine details
- Medicine name:
- azacitidine (Vidaza)
- SMC ID:
- 1175/16
- Indication:
- Treatment of adult patients aged 65 years or older who are not eligible for haematopoietic stem cell transplantation (HSCT) with acute myeloid leukaemia (AML) with >30% marrow blasts according to the World Health Organisation (WHO) classification.
- Pharmaceutical company
- Celgene Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 11 July 2016